MetaCap

Enliven Therapeutics (ELVN) vs Tango Therapeutics (TNGX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Tango Therapeutics (TNGX) has outperformed Enliven Therapeutics (ELVN) over the past year, gaining 116.7% versus a gain of 113.9%. Over five years, ELVN leads with a +254.6% price change compared with +110.0% for TNGX. Tango Therapeutics is the larger company by market cap ($3.68 billion vs $3.42 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ELVN+113.93%TNGX+116.65%
+241%+99%-43%
Nov 21, 20251 yearNov 20, 2026
ELVN+252.50%TNGX+81.54%
+380%+134%-113%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ELVN versus TNGX key metrics
MetricELVNTNGX
Share price$46.53$21.73
Market cap$3.42B$3.68B
1-day change+0.26%-4.32%
YTD return+202.14%+145.26%
1-year return+113.93%+116.65%
5-year return+254.65%+109.95%
EPS (TTM)$-1.69$-1.38
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$62.38M
Revenue growth (YoY)—+48.29%
Net income (latest FY)$-103.69M$-101.59M
Operating margin—-178.39%
Net margin—-162.85%
52-week high$62.32$34.39
52-week low$14.79$8.30
Distance from 52-week high-25.34%-36.81%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+59.75%+116.29%
Average volume1.36M3.41M
Shares outstanding73.60M169.46M
Employees65137
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Enliven Therapeutics

ELVN stock →

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees

About Tango Therapeutics

TNGX stock →

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 137 employees

ELVN vs TNGX FAQ

Which is bigger, Enliven Therapeutics or Tango Therapeutics?

Tango Therapeutics (TNGX) is larger, with a market capitalization of $3.68B compared with $3.42B for Enliven Therapeutics (ELVN).

Which stock has performed better over the past year, ELVN or TNGX?

TNGX returned +116.65% over the past 12 months, compared with +113.93% for ELVN (price return, excluding dividends). Past performance does not predict future results.

Are Enliven Therapeutics and Tango Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons